Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth

详细信息    查看全文

• 作者：Hao Yang^a ; ^b ; ^c ; ¹ ; Juan Wang^a ; ^b ; ¹ ; Jin-hong Fan^a ; Ya-qi Zhang^a ; Jun-xian Zhao^a ; Xiao-jun Dai^a ; ^d ; Qi Liu^a ; ^b ; Yan-jun Shen^a ; ^b ; Chang Liu^a ; Wei-dong Sun^a ; ^d ; ^{zyykjc@sina.com} ; Yun Sun^a ; ^b ; ^{ysun@yzu.edu.cn}
• 关键词：Ilexgenin A ; Angiogenesis ; STAT3 ; PI3K ; Synergy effect ; Sorafenib
• 刊名：Toxicology and Applied Pharmacology
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：315
• 期：Complete
• 页码：90-101
• 全文大小：2664 K
• 卷排序：315

文摘

Ilexgenin A exerts anti-inflammatory and anti-angiogenesis effects in hepatoma. Ilexgenin A may exert these effects through inhibition of STAT3 and PI3K pathways. Ilexgenin A exhibits synergistic effects with Sorafenib on hepatoma growth. Ilexgenin A can remedy the potential liver toxicity of Sorafenib.